NeOnc CEO Accelerates Insider Buying with $500K+ Investment Ahead of Imminent NEO100 Phase 2a Data Catalysts
NeOnc Technologies Holdings' CEO has invested over $500,000 in company shares recently, reflecting strong confidence ahead of important clinical trial data from its Phase 2a NEO100 study in recurrent IDH1-mutant high-grade glioma. This insider buying underscores optimism about the company’s innovative CNS cancer therapies designed to overcome the b…